Streptozotocin induces renal proximal tubular injury through p53 signaling activation
Kunihiro Nakai, Minato Umehara, Atsushi Minamida, Hiroko Yamauchi-Sawada, Yasuto Sunahara, Yayoi Matoba, Natsuko Okuno-Ozeki, Itaru Nakamura, Tomohiro Nakata, Aya Yagi-Tomita, Noriko Uehara-Watanabe, Tomoharu Ida, N. Yamashita, Michitsugu Kamezaki, Yuhei Kirita, Eiichi Konishi, Hiroaki Yasuda, Satoaki Matoba, Keiichi Tamagaki, Tetsuro Kusaba
Abstract
Streptozotocin (STZ), an anti-cancer drug that is primarily used to treat neuroendocrine tumors (NETs) in clinical settings, is incorporated into pancreatic β-cells or proximal tubular epithelial cells through the glucose transporter, GLUT2. However, its cytotoxic effects on kidney cells have been underestimated and the underlying mechanisms remain unclear. We herein demonstrated that DNA damage and subsequent p53 signaling were responsible for the development of STZ-induced tubular epithelial injury. We detected tubular epithelial DNA damage in NET patients treated with STZ. Unbiased transcriptomics of STZ-treated tubular epithelial cells in vitro showed the activation of the p53 signaling pathway. STZ induced DNA damage and activated p53 signaling in vivo in a dose-dependent manner, resulting in reduced membrane transporters. The pharmacological inhibition of p53 and sodium-glucose transporter 2 (SGLT2) mitigated STZ-induced epithelial injury. However, the cytotoxic effects of STZ on pancreatic β-cells were preserved in SGLT2 inhibitor-treated mice. The present results demonstrate the proximal tubular-specific cytotoxicity of STZ and the underlying mechanisms in vivo. Since the cytotoxic effects of STZ against β-cells were not impaired by dapagliflozin, pretreatment with an SGLT2 inhibitor has potential as a preventative remedy for kidney injury in NET patients treated with STZ.